Frontlight ResearchEarly access
Not yet taking people in FrancePhase 3
Fluoxetine added to usual treatment for children with hard-to-treat epilepsy
Tests fluoxetine against placebo in children with epilepsy that medicines do not control.
Key facts
- Who runs it
- Centre Hospitalier Regional De Marseille
- Where
- Bordeaux, Lyon Cedex 04, Marseille, Montpellier Cedex 5, Paris, and Toulouse Cedex 9, FranceSee the 6 sites
- Trial code
- Registry title
- Efficacy of FLUOXETINE in children with drug-resistant, complex and rare epilepsy (FLUOXEPIL)
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 100 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 16 Apr 2029
- Type of study
- Interventional
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 8 to 17 with hard-to-treat, complex or rare epilepsy that still causes seizures despite several medicines.
- Age
- 8 to 17 years
- Sex
- All sexes
- Disease stage
- Drug-resistant focal or generalized epilepsy; rare or complex epilepsy such as developmental and epileptic encephalopathy, severe structural epilepsy or rare epileptic syndromes. At least 3 seizures a month on average. Daytime seizures with loss of consciousness and/or falls, and/or nocturnal seizures with blue skin colour.
- Earlier treatment
- At least 4 anti-seizure medicines have been tried without controlling the seizures. Fewer than 5 anti-seizure medicines at the same time. The dose has been stable for at least 1 week before screening. No indication for epilepsy surgery, or surgery not possible, failed or refused.
Main reasons for not taking part
- Pregnant or breastfeeding
- Weight under 20 kg (44 lb)
- Known QT prolongation, or heart, kidney or liver problems
- Previous mania or hypomania, high blood pressure, diabetes or bleeding disorder
- Taking oral anticoagulants, a monoamine oxidase inhibitor or metoprolol
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Signed and dated informed consent form by the two parents (or one, if single-parent family, as documented in the medical file)
- Patient for whom at least 4 treatments (anti-seizure medications) have been prescribed, alone or in combination, at appropriate dosage, without controlling the seizures
- Patient exhibiting daytime seizures with loss consciousness and/or leading to falls, and/or cyanotic nocturnal seizures
- Patient presenting at least 3 seizures/months on average
- Less than five concomitant anti-seizure medications (ASMs) at time of inclusion
- Patient having a dose of ASMs which is stable for at least one week prior to screening
- For girls of childbearing potential, willing to use a highly effective contraceptive method throughout the study and until 6 weeks after the end of the treatment
- Patient with no indication or epilepsy surgery, contra-indication of the surgery or failure/refusal of epilepsy surgery
- Patient having the ability to take oral medication
- Patient who is a beneficiary of or affiliated to a social security scheme
- Documented willingness of both parents to comply with all study procedures for the duration of the study (or one if single-parent family)
- Child or adolescent aged of 8 – 17 years old
- Child assent for his/her participation to the research
- Patient with rare / complex epilepsy: Developmental and Epileptic Encephalopathy, structural severe epilepsies, rare epileptic syndromes as defined by the International League Against Epilepsy
- Patient presenting drug-resistant focal or generalized epilepsy according to the ILAE definition
Who cannot take part
- Patient with previous history of mania/hypomania
- Concomitant use of monoamin oxidase inhibitor or metoprolol
- Patient with a history of bleeding disorders
- Patient having a known history of diabete(s)
- Patient with history or presenting any abnormality of renal, hepatic or cardiac function
- Patient with treated or untreated hypertension
- Patient having a score of 23 or more obtained with the Neurological Disorders Depression Inventory-Epilepsy for Youth scale or any suicidal idea
- Patient presenting contraindications to fluoxetine: hypersensitivity to fluoxetine and/or excipients
- Patient with known QT prolongation
- Patient presenting with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome
- Patient participating to another clinical trial
- Patient not in capacity to consent and/or without legal representative present to receive the information and give consent for the patient’s participation
- Patient taking oral anticoagulants
- Pregnant or breastfeeding women
- Patient under 20 kg at the screening visit
- Patient with limited French proficiency
Where in France
- Pellegrin HospitalBordeaux, FranceNot yet recruiting
- Hospital La Croix Rousse HclLyon Cedex 04, FranceNot yet recruiting
- Institut Des Neurosciences De La TimoneMarseille, FranceNot yet recruiting
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceNot yet recruiting
- Robert Debre University HospitalParis, FranceNot yet recruiting
- Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceNot yet recruiting
About the trial
What the trial wants to find out
To compare the efficacy of fluoxetine plus anti-seizure treatment as usual (TAU) versus placebo plus TAU in reducing the frequency of seizures in children of at least 8 years of age having drug-resistant epilepsy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Randomized double-blinded placebo-controlled study of the efficacy of fluoxetine in add-on treatment of drug-resistant, complex and rare epilepsy in children aged 8 years and older: use of a design evaluating the time to reach a defined number of seizures for each child during the prospective observational phase (FLUOXEPIL)
- Plain-language title
- Fluoxetine added to usual treatment for children with hard-to-treat epilepsyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 15 September 2026